Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Whitehall-Robins' Orudis KT

This article was originally published in The Tan Sheet

Executive Summary

Whitehall-Robins' Orudis KT: FDA suggests company should "submit the blend uniformity and content uniformity validation data to the NDA reviewer at the Center for Drug Evaluation & Research for evaluation" in the event the company decides to resume production of the OTC NSAID at its Guayma, Puerto Rico manufacturing facility. FDA makes the suggestion in a Sept. 25 warning letter to the American Home Products firm. The warning letter follows a June 9-Aug. 11 inspection of the facility and FDA observations about out-of-spec lots and failure to have adequate acceptance criteria for testing of Orudis KT. As a result of the agency's FD 483 inspections report, Whitehall-Robins initiated a recall of one lot of the product Sept. 9...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087672

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel